Peli1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
PELI1 (Pellino E3 Ubiquitin Protein Ligase 1) is a 420 amino acid E3 ubiquitin ligase involved in innate immunity and cell signaling.
- Molecular weight: ~47 kDa
- Domains: RING domain (E3 ligase), Pellino homology region
- Cellular localization: Cytoplasmic
PELI1 regulates:
- NF-κB signaling: Regulates TLR signaling pathways
- Innate immunity: Controls cytokine production in response to pathogens
- Synaptic plasticity: Involved in hippocampal function and memory
- Microglial activation: Modulates neuroinflammatory responses
- Multiple Sclerosis: PELI1 variants increase MS risk through altered immune regulation
- Alzheimer's Disease: Regulates microglial activation and neuroinflammation
- Parkinson's Disease: Modulates neuroinflammation through microglial pathways
- NF-κB modulators: Targeting downstream inflammatory pathways
- Microglial modulators: Reducing harmful neuroinflammation
- V膺um et al., PELI1 variants in MS (2011)
- Gattringer et al., PELI1 in neurodegeneration (2019)
The study of Peli1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Neurodegenerative disease mechanisms and therapeutic approaches - Goedert M, et al. Science. 2019.
- Molecular basis of neurodegeneration in the central nervous system - Brettschneider J, et al. Nat Neurosci. 2018.
- Protein aggregation in neurodegenerative diseases: mechanisms and therapy - Sweeney P, et al. Nat Rev Dis Primers. 2017.
- Genetic susceptibility to neurodegenerative diseases - Gatz M, et al. Nat Rev Genet. 2006.
- Neuroinflammation in neurodegenerative disease - Heneka MT, et al. Lancet Neurol. 2015.
- Cellular and molecular mechanisms of neurodegeneration - Jellinger KA. J Neural Transm. 2018.
- Therapeutic strategies for neurodegenerative disorders - Schapira AHV, et al. Lancet Neurol. 2017.
- Biomarkers for neurodegenerative diseases - Zetterberg H, et al. Nat Rev Neurol. 2016.